Health Care · Services-Medical Laboratories · Nasdaq · CIK 1217234 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $35.41Day −0.95%Mkt cap $1.8B1Y +178.4%Off 52W high −12.5%Vol (1Y) 70.9%
Daily closing price, split-adjusted to the current basis; 3y shown of 3,024 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest12.0% of sh out |
| Days to cover7.8d |
| 13F net flow (QoQ)+2.53% |
| Top-10 13F concentration46.7% |
| Next report (est.)2026-10-29 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$412.8M |
| Earnings (TTM)-$8.2M |
| ROE−6.3% |
| Net margin−5.6% |
| ROIC−9.7% |
| Sales growth 3Y5.7% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+88.0% |
| 1Y+178.4% |
| 3Y+224.6% |
| 5Y−59.5% |
| 10Y+668.1% |
| Since incept. (ann.)+12.0% |
Total return through 2026-07-29 · series begins 2014-07-17. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)70.9% |
| Ann. volatility (3Y)77.3% |
| Sharpe (1Y)1.78 |
| Sharpe (3Y)0.89 |
| Max drawdown (1Y)−23.6% |
| Max drawdown (3Y)−66.0% |
| Beta (3Y vs SPY)3.94 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 4.5M | $79M | 8.75% | −2.8% |
| BAMCO INC /NY/ | 3.3M | $58M | 6.46% | +5.7% |
| STATE STREET CORP | 2.8M | $48M | 5.34% | +0.8% |
| ARK Investment Management LLC | 2.2M | $39M | 4.31% | +4.3% |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2.2M | $38M | 4.24% | +0.0% |
| BRAIDWELL LP | 2.2M | $38M | 4.21% | +37.1% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.2M | $38M | 4.18% | new |
| Boston Partners | 1.9M | $33M | 3.65% | +108.8% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 101.7% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 6,892,213 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-04-28 | $0.05 | — | $117.7M | +39.0% |
| 2025-12-31 | 2026-02-24 | — | — | $108.4M | +25.2% |
| 2025-09-30 | 2025-11-04 | $0.03 | — | $100.1M | +20.7% |
| 2025-06-30 | 2025-08-06 | −$0.16 | — | $86.7M | −6.1% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-29 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
